Per BioSpace's coverage of the Monday session, the Center for Drug Evaluation and Research (CDER), now led by Director Michael Davis, absorbed testimony from clinicians, attorneys, and pharmaceutical executives on what guardrails the agency should embed into forthcoming approvals. The meeting signals that pharmacovigilance architecture for this therapeutic class is being negotiated while the first candidates already sit within measurable proximity to regulatory decisions.
Two identifiable threshold positions
The hearing produced two distinct camps on risk mitigation intensity. Edward Jacobs, associate director of HOPE – The Hub at Oxford for Psychedelic Ethics, argued for initial caution, stating that "it's better to start with stronger protections and adjust them as the evidence accumulates than to start with weaker protections and tighten them after harm." Laurel Kilgour, an attorney with the Psychedelic Bar Association, countered that excessive regulation carries its own quantifiable risk — namely, that "an overly zealous risk mitigation framework can undermine safety by pushing people toward underground alternatives with no oversight or foreclosing access altogether." Jefferies analysts described the overall tone as constructive, with majority support for an FDA psychedelic pathway, while a minority urged the agency to embed adverse event monitoring obligations directly into approval conditions.
These positions frame the variance the FDA must reconcile before issuance of any approval letter.
Approaching candidates and the pharmacovigilance calculus
Two developments compress the timeline. Compass Pathways' COMP360, a psilocybin-based depression therapy, could launch early next year. Definium Therapeutics recorded a third Phase 3 win on Monday for DT120, an oral LSD candidate. Jefferies recently projected peak sales above $5 billion for Johnson & Johnson's esketamine-based Spravato, launched in 2019 — a commercial benchmark that contextualizes the urgency behind the standards debate.
Stakeholders uniformly emphasized that altered states during administration and elevated patient vulnerability alter the safety calculus relative to conventional psychotropics. They urged FDA officials to codify supervision requirements — specifically, the stipulation that clinicians trained in psychedelic-specific protocols must administer these therapies — within the approval language itself. Adverse event monitoring, several experts argued, belongs in pre-market risk evaluation and mitigation strategies rather than deferred to post-market surveillance. The objective: prevent the pattern observed in early-stage approvals, where gaps in monitoring only surface after harm occurs.
Compliance checkpoints for clinical integration
For healthcare facilities and consulting practices preparing deployment protocols, the evidence establishes three verification sequences:
1. Practitioner credentialing documentation — verification that any clinician authorized to administer these agents holds certification in psychedelic-specific administration, with the FDA expected to specify training thresholds in approval language.
2. Adverse event capture infrastructure — capacity for standardized event reporting that integrates with FDA post-market surveillance systems, since embedded monitoring obligations are a probable approval condition.
3. Patient screening and consent documentation — intake procedures calibrated for the vulnerability considerations cited throughout testimony, including explicit consent for altered-state administration.
Sobering risk assessment
Regulatory variance persists. The FDA retains discretion to either prescribe specific risk mitigation conditions or defer to standard post-market pharmacovigilance. The hearing signals probable preference for the former. Facilities establishing protocols before definitive guidance arrives operate under elevated contingency — each protocol template will likely require substantive revision once FDA approval language is published. The threshold for compliant deployment has not been codified; the fiscal and clinical exposure for early movers is accordingly quantifiable but not yet insulated.